POXEL was set-up to find innovative solutions for metabolic diseases management

Poxel is a Royalty Income Pharmaceutical Company (RIPCO) aiming at progressing promising assets for metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing products to pharmaceutical companies.

Its pipeline consists in innovative products with original mechanism of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies.

The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the total product life cycle. Poxel’s team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on metabolic diseases.

A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets.

Poxel’s team will be advised by a rewarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe.
Poxel will start the development of its core assets, while seeking funding in order to create significant value from its unique pipeline.